Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study
Original Article|Updated:2025-12-19
|
Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study
Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study
Chinese Journal of Integrative Medicine2025年31卷第12期 页码:1059-1068
Affiliations:
1.Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing (100191), China
2.State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing (100191), China
3.Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing (100191), China
4.Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing (100191), China
Author bio:
Prof. LI Dong, E-mail: lidong6512@sina.com;
Prof. LI Rong, E-mail: roseli001@sina.com
Funds:
the National Natural Science Foundation of China(82074193);Youth Fund of the National Natural Science Foundation of China(82301962);the Special Grant for Capital Health Research and Development(2022-2-4097);Key Clinical Projects of Peking University Third Hospital(BYSYZD2024008);Capital Medical Research & Development Fund(2024-2-4099)
XIN Xi-yan, WANG Yang, ZHANG Hua, 等. Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study[J]. Chinese Journal of Integrative Medicine, 2025,31(12):1059-1068.
XIN Xi-yan, WANG Yang, ZHANG Hua, et al. Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study[J]. Chinese Journal of Integrative Medicine, 2025, 31(12): 1059-1068.
XIN Xi-yan, WANG Yang, ZHANG Hua, 等. Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study[J]. Chinese Journal of Integrative Medicine, 2025,31(12):1059-1068. DOI: 10.1007/s11655-025-4213-2.
XIN Xi-yan, WANG Yang, ZHANG Hua, et al. Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study[J]. Chinese Journal of Integrative Medicine, 2025, 31(12): 1059-1068. DOI: 10.1007/s11655-025-4213-2.
Wenyang Lishui Formula Ameliorates Symptoms of Ovarian Hyperstimulation Syndrome: A Prospective Cohort Study
摘要
Abstract
Objective:
2
To study the clinical efficacy of Wenyang Lishui Formula (WYLSF) in preventing ovarian hyperstimulation syndrome (OHSS) and explore the suitable range of estradiol (E
2
) on the human chorionic gonadotropin (HCG) day in patients with OHSS using WYLSF.
Methods:
2
Part Ⅰ: eligible patients at high risk for OHSS undergoing ovulation induction between January and December
2023 were randomized into 2 groups based on the actual treatment. The treatment group received 200 mL WYLSF formula twice daily for 5 days after oocyte retrieval in a combination of lifestyle coaching (LC) intervention including regular diet and exercise
whereas the LC group received LC intervention alone. The incidence of OHSS
OHSS self-assessment scales
changes in E
2
levels on HCG day and 5 days after oocyte retrieval
ovarian morphology changes
and menstrual recovery were compared between the two groups. Part Ⅱ: patients at high risk for OHSS treated with WYLSF were studied. The optimal E
2
threshold on the HCG day was determined using the maximum selection test
and a multivariate analysis was adopted to compare the relationship between different E
2
levels on HCG day and hospitalization rate
incidence of moderate to severe OHSS
and self-assessment scales
to explore the preventive effect of WYLSF on OHSS in patients with varying E
2
levels.
Results:
2
A
total of 120 patients were included in the Part Ⅰ analysis. The treatment group (60 cases) showed a significant reduction in the incidence
duration
and severity of abdominal distension
as well as the incidence of vomiting compared with the LC group (
P
<
0.05). The post-retrieval E
2
levels in the treatment group decreased significantly more (
P
=0.032). Among 1
652 patients treated with WYLSF in the Part Ⅱ
90 patients with ≤10092 pmol/L
159 with
>
31074 pmol/L
and 1
403 in the middle range group were formed based on E
2
levels on HCG day in Part two analysis. Univariate and regression analyses showed that patients with E
2
levels
>
31073 pmol/L had a significantly higher incidence of moderate to severe OHSS compared to those with E
2
levels ≤10092 pmol/L (
P
<
0.05).
Conclusions:
2
WYLSF can effectively reduce specific symptoms in high-risk OHSS patients after ovulation induction and significantly lower E
2
levels. It may be more suitable for high-risk OHSS patients with E
2
levels
<
31073 pmol/L on HCG day. (Registration No. MR-11-23-032493
https://www.medicalresearch.org.cn/login)
关键词
Keywords
references
The trial reading is over, you can activate your VIP account to continue reading.
Inhibitory Effects of Nardostachys Jatamansi DC. Volatile Oil on Psychological Factors SP/CORT-Induced Hyperpigmentation
Lu'e Biyan Formula for Treatment of Allergic Rhinitis Patients with Fei (Lung)-Qi Deficiency-Coldness Syndrome: A Randomized, Double Blind, and Placebo-Controlled Trial*
Dihuang Yinzi Regulates cAMP/PKA/CREB-BDNF to Improve Synaptic Plasticity in APP/PS1 Mice: A Study Based on Brain Metabolomics*
Suanzaoren Decoction Alleviates Anxiety- and Depression-Like Behaviors Induced by Chronic Restraint Stress via Regulating Pyramidal Neuron Activity in Basolateral Amygdala of Mice*
Liujunzi Decoction Regulated Intestinal Flora Homeostasis to Relieve Lung–Gut Axis Inflammation in Asthma Flora Disorder Mice: Possibly Related to GATA3/ILC2*
相关作者
YANG Man
CHENG Kang
GU Jie
WU Hua-li
LI Yi-ming
JIA Ming-yue
ZHANG Mei-yi
XIAO Si-yao
相关机构
Department of Traditional Chinese Medicine Chemistry, School of Pharmacy, Shanghai University of Traditional Chinese Medicine
Shanghai Inoherb Cosmetics Co., Ltd.
Department of Pulmonary and Critical Care Medicine/Department of Integrated Traditional Chinese and Western Medicine for Pulmonary Diseases Part 1, National Center for Integrative Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital; National Center for Respiratory Medicine; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases
Graduate School of Beijing University of Chinese Medicine
School of Basic Medicine, Heilongjiang University of Chinese Medicine